A three-protein signature and clinical outcome in esophageal squamous cell carcinoma.
A three-protein signature and clinical outcome in esophageal squamous cell carcinoma.
复制标题
食管鳞状细胞癌的三蛋白特征和临床结果。
DOI：
10.18632/oncotarget.3102
复制
发表时间：
2015-03-10
期刊：
影响因子：
--
通讯作者：
Xu LY
中科院分区：
文献类型：
--
作者：
Cao HH;Zhang SY;Shen JH;Wu ZY;Wu JY;Wang SH;Li EM;Xu LY
目前的分期不足以准确预测食道鳞状细胞癌(ESCC)的临床结果并确定治疗选择，从单纯手术到强化多模式方案不等。本研究的目的是探讨以免疫组织化学为基础的三蛋白信号模型在ESCC患者中的预后价值。我们用组织芯片技术检测了110例福尔马林固定、石蜡包埋的食道切除标本中Annexin II、cofilin 1、Ezrin、Fasin、kindlin-2、moesin、MTSS1、myosin-9、profilin-1、rac1、Radixin、ROCK2、talin、tensin和Villin 1的蛋白表达。从蛋白质簇Annexin II、kindlin-2和myosin-9中获得的三种蛋白质特征被147个独立样本的TMAS验证。在世代和验证数据集中，三蛋白信号的表达对食管鳞癌的总生存期(OS)和无病生存期(DFS)具有很高的预测性。回归分析表明，这三种蛋白特征是OS和DFS的独立预测因子。此外，这3个生物标志物组合的预测能力比单个生物标志物的预测能力更强。这项研究证明了一个临床适用的预后模型，它可以准确地预测ESCC患者的生存和/或肿瘤复发，因此可以作为对当前风险分层方法的补充。
Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemistry-based three-protein signature model in patients with ESCC. We determined the protein expression of Annexin II, cofilin 1, ezrin, fascin, kindlin-2, moesin, MTSS1, myosin-9, profilin-1, Rac1, radixin, ROCK2, talin, tensin and villin 1 in a test cohort including 110 formalin-fixed, paraffin-embedded esophageal curative resection specimens by tissue microarrays (TMAs). A three-protein signature elicited from the protein cluster, Annexin II, kindlin-2, and myosin-9, was validated by TMAs on an independent cohort of 147 specimens. The expression of three-protein signature was highly predictive of ESCC overall survival (OS) and disease-free survival (DFS) in both generation and validation datasets. Regression analysis shows that this three-protein signature is an independent predictor for OS and DFS. Furthermore, the predictive ability of these 3 biomarkers in combination is more robust than that of each individual biomarker. This study demonstrates a clinically applicable prognostic model that accurately predicts ESCC patient survival and/or tumor recurrence, and thus could serve as a complement to current risk stratification approaches.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-11-2483
发表时间：
2012-04-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Garcia I;Mayol G;Ríos J;Domenech G;Cheung NK;Oberthuer A;Fischer M;Maris JM;Brodeur GM;Hero B;Rodríguez E;Suñol M;Galvan P;de Torres C;Mora J;Lavarino C
通讯作者：
Lavarino C
DOI：
10.1093/annonc/mds080
发表时间：
2012-11
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Prat A;Parker JS;Fan C;Cheang MCU;Miller LD;Bergh J;Chia SKL;Bernard PS;Nielsen TO;Ellis MJ;Carey LA;Perou CM
通讯作者：
Perou CM
影响因子：
3.6
作者：
Sharma, Meena R.;Koltowski, Lauren;Sharma, Mahesh C.
通讯作者：
Sharma, Mahesh C.
影响因子：
3.3
作者：
Kato, K;Shiozawa, T;Konishi, I
通讯作者：
Konishi, I
影响因子：
158.5
作者：
Lossos, IS;Czerwinski, DK;Levy, R
通讯作者：
Levy, R